Results confirmed: Selfapy’s medical product also shows efficacy in men with generalised anxiety disorder

In December 2023, the Federal Institute for Drugs and Medical Devices (BfArM) extended the reimbursement of Selfapy’s online course for generalised anxiety disorder to men.

The BfArM thus confirms the results of additional real-world evidence (RWE), which shows that Selfapy’s product also significantly reduces anxiety symptoms and improves health-related quality of life in men with generalised anxiety disorder. Selfapy’s online course for generalised anxiety disorder can therefore be prescribed to all patients between the ages of 18 and 65 and reimbursed by all statutory health insurance companies nationwide. The evaluation of the RWE with a total of 56 male participants shows a significant reduction in anxiety symptoms by an average of 37.96%. In addition, the participants reported a significant improvement in health-related quality of life by an average of 47.30 %. The positive treatment effect could therefore also be demonstrated in men with generalised anxiety disorder.

Click here for the press release: link